Vaccinex Inc (VCNX)
OTHER OTC:VCNX
Top Page
Vaccinex
(OTC:VCNX)
Select Model
Select Model
Rating:47Neutral
Price Target:
$1.00
▲(44.93% Upside)
Action:ReiteratedDate:01/16/26
The score is primarily held down by very weak financial fundamentals (losses, negative equity, and cash burn). Technical signals are constructive and provide partial support, but valuation is constrained by negative earnings and no dividend data.
Positive Factors
Proprietary monoclonal antibody platform
Owning a proprietary monoclonal antibody platform and a lead clinical asset (VAC-1) provides durable R&D leverage. A validated platform can enable pipeline expansion, attract partnerships or licensing, and create long-term value if clinical progress continues.
Negative Factors
Negative stockholders' equity
Negative equity is a structural solvency concern that limits borrowing capacity and increases refinancing risk. It can force dilutive capital raises, constrain strategic flexibility, and deter potential partners or acquirers unless corrected by sustained profit or recapitalization.
Read all positive and negative factors
Positive Factors
Negative Factors
Proprietary monoclonal antibody platform
Owning a proprietary monoclonal antibody platform and a lead clinical asset (VAC-1) provides durable R&D leverage. A validated platform can enable pipeline expansion, attract partnerships or licensing, and create long-term value if clinical progress continues.
Read all positive factors
Vaccinex (VCNX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$3.05M
Dividend YieldN/A
Average Volume (3M)1.22K
Price to Earnings (P/E)―
Beta (1Y)2.56
Revenue Growth5.44%
EPS Growth84.28%
CountryUS
Employees23
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)N/A
Shares Outstanding2,676,637
10 Day Avg. Volume776
30 Day Avg. Volume1,224
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)-0.83
Price to Sales (P/S)3.42
P/FCF Ratio-0.13
Enterprise Value/Market Cap0.65
Enterprise Value/Revenue3.28
Enterprise Value/Gross Profit3.43
Enterprise Value/Ebitda-0.11
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Vaccinex Business Overview & Revenue Model
Company Description
Vaccinex, Inc. (VCNX) is a biotechnology company focused on developing targeted therapeutics for the treatment of cancer and neurodegenerative diseases. The company specializes in monoclonal antibody technology and has several proprietary product ...
How the Company Makes Money
Vaccinex generates revenue through multiple channels, primarily focused on the development and commercialization of its therapeutic products. The company earns money through grant funding, partnerships, and collaborations with larger pharmaceutica...
Vaccinex Financial Statement Overview
Summary
Income Statement
35
Negative
Balance Sheet
20
Very Negative
Cash Flow
40
Negative
| Breakdown | Dec 2024 | Mar 2024 | Mar 2023 | Mar 2022 | Dec 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 601.00K | 570.00K | 100.00K | 900.00K | 50.00K |
| Gross Profit | 601.00K | 570.00K | 68.00K | 731.00K | 48.00K |
| EBITDA | -18.54M | -19.75M | -19.61M | -21.40M | -28.05M |
| Net Income | -18.63M | -20.25M | -19.72M | -22.38M | -28.85M |
Balance Sheet | |||||
| Total Assets | 2.60M | 3.63M | 7.98M | 9.84M | 11.70M |
| Cash, Cash Equivalents and Short-Term Investments | 1.11M | 1.53M | 6.39M | 8.59M | 10.60M |
| Total Debt | 25.00K | 247.00K | 485.00K | 390.00K | 9.21M |
| Total Liabilities | 5.08M | 5.94M | 2.78M | 2.43M | 14.31M |
| Stockholders Equity | -2.49M | -2.31M | 5.19M | 7.41M | -26.57M |
Cash Flow | |||||
| Free Cash Flow | -16.21M | -17.30M | -19.17M | -25.33M | -28.94M |
| Operating Cash Flow | -16.19M | -17.23M | -19.07M | -25.30M | -28.65M |
| Investing Cash Flow | -22.00K | -67.00K | -99.00K | -32.00K | -290.00K |
| Financing Cash Flow | 15.78M | 12.45M | 16.98M | 23.32M | 36.76M |
Vaccinex Technical Analysis
Positive
0.69
Price Trends
1.09
Positive
0.91
Positive
0.81
Positive
Market Momentum
>-0.01
Negative
55.27
Neutral
69.00
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For VCNX, the sentiment is Positive. The current price of 0.69 is below the 20-day moving average (MA) of 0.91, below the 50-day MA of 1.09, and below the 200-day MA of 0.81, indicating a bullish trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 55.27 is Neutral, neither overbought nor oversold. The STOCH value of 69.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for VCNX.
Vaccinex Risk Analysis
Vaccinex disclosed 49 risk factors in its most recent earnings report. Vaccinex reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Vaccinex Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | $3.05M | -0.11 | 1406.28% | ― | 5.44% | 84.28% | |
46 Neutral | $10.27M | -0.10 | -209.36% | ― | ― | 83.25% | |
43 Neutral | $3.82M | -0.12 | -215.04% | ― | -100.00% | 93.82% | |
42 Neutral | $4.20M | -2.23 | -0.40% | ― | ― | 96.26% | |
41 Neutral | $14.07M | -0.15 | -356.99% | ― | ― | 54.62% |
* Healthcare Sector Average
VCNX
Vaccinex
1.14
0.39
51.87%
TOVX
Theriva Biologics
0.22
-0.92
-80.44%
GTBP
GT Biopharma
0.45
-1.95
-81.42%
REVB
Revelation Biosciences
1.13
-31.27
-96.51%
CERO
CERo Therapeutics Holdings
0.03
-14.99
-99.78%
AZTR
Azitra Inc
0.24
-1.80
-88.38%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.